ARCHIVES

Perjeta Neoadjuvant Therapy Granted Accelerated Approval In HER2 Breast Cancer

This article is from The Cancer Letter archive.

Vol. 36 No. 10 | October 25, 2013

Download PDF Visit The Full Archive

Related Articles

Talactoferrin Second-Line Therapy Increases Survival In Stage IIIB/IV

October 28, 2011

FTE Shortage Hurting Cancer and AIDS Research, Advisors Told; NCI Seeks Major Share Of New Slots

October 14, 1988

NCi Advisors Approve New SPORE Grant Program In Cancer Communications.

December 1, 2000

Battelle Wins Big Toxiology Contract

March 22, 1974

With NIH “Accountability” As Background, Advocates Support Budget Increases.

March 30, 2001

DCPC Board Approves $40 Million In New Concepts, Including Three In Breast Cancer, One In Melanoma

October 12, 1984